New Deer Amniotic Fluid Stem Cell Exosome Skincare Series Enters China’s High-End Beauty Market
U-NEURON reaches a new operational milestone! The entry of its novel deer amniotic fluid stem cell exosome skincare line into Mainland China’s premium beauty sector is set to propel this year’s overall operational performance to new heights.
President Dr. Hsiao-Min Huang pictured center. (Photo / Provided by Chlitina Group)

Key Highlights & Market Expansion Strategic Deployment in Overseas Premium Beauty Markets Taiwan’s pioneering stem cell firm, U-NEURON (6973-TW), recently announced a major operational milestone. On May 9, the company was invited to attend the grand launch event hosted by its key strategic partner, Chlitina Group (4137-TW), in Wuhan, Mainland China—the “CHLITINAGolden Bandage Global Debut Launch Event.” The event generated strong enthusiasm and a flood of advance presale orders. This success marks the official entry of skincare products built upon U-NEURON’s world-exclusive “Deer Amniotic Fluid Stem Cell Exosome” patented technology into Mainland China’s high-end beauty market. Aligned with Chlitina’s product rollout schedule and marketing campaigns, these initial orders provide strong revenue visibility and robust shipment momentum for U-NEURON throughout the year. Technological Superiority & Humane Sourcing A key active ingredient in the newly launched “Skin Radiance Refining Series” is D-AFE® (Deer Amniotic Fluid Extract), isolated through U-NEURON’s proprietary amniotic fluid stem cell culture and separation platform. Sourced in collaboration with certified ethical deer farms in Taiwan, the extraction process is entirely non-harmful, low-risk, and conducted under strict sanitary and safety standards.
Compared to other stem cell sources (such as adipose, umbilical cord, or bone marrow), amniotic fluid stem cells represent a fetal-stage cell type closer to embryonic stem cells in their regenerative and differentiation capabilities. Free from ethical controversy, D-AFE® offers rarity, high tissue-repair capacity, and potent anti-aging properties.

Furthermore, D-AFE® has secured an official International Nomenclature of Cosmetic Ingredients (INCI) registration, confirming its international credibility and regulatory compliance for global cosmetic manufacturing, while reinforcing U-NEURON’s position as a premier ingredient supplier in regenerative aesthetics. Dual-Engine Business Model: Commercialization Driving Clinical R&D Over its 10-year history, U-NEURON has built its core competencies around amniotic fluid stem cell platforms, operating through two strategic pillars: Therapeutics Pipeline (Human Amniotic Fluid Stem Cells): Leveraging the neural repair capabilities of human amniotic fluid stem cells, U-NEURON is advancing clinical drug candidates, including UA002 for erectile dysfunction and UB003 for dry eye syndrome. Cosmeceuticals & Consumer Wellness (Deer Amniotic Fluid Stem Cell Derivatives): Driven by strong domestic demand for D-AFE® skincare products via key distribution channels, cumulative revenue for the first four months of the year reached NT$23.374 million—representing a 63.32% year-over-year growth (an 80.95% surge in absolute terms compared to the same period last year).
U-NEURON Chairman Dr. Frank Chien expressed confidence that as Chlitina expands retail distribution across its network of nearly 5,000 physical salons in Mainland China and Taiwan, product shipments will accelerate, injecting strong growth momentum into second-half operations. Market Outlook & Future Strategy According to WiseGuy Reports’ Global Anti-Aging Beauty Products Market Research Report, the global anti-aging skincare market reached US$206.72 billion in 2024 and is projected to expand at a CAGR of 4.79% to reach US$300.6 billion by 2032, driven by population aging, increased personal care awareness, rising disposable income, and biotech advancements. Looking ahead to 2025, U-NEURON maintains a prudently optimistic outlook. Beyond its exclusive supply arrangement with Chlitina inMainlandChina and Taiwan, U-NEURON continues to leverage its exosome platform to engineer custom active ingredients for medical aesthetic channels, including hair restoration formulations and dental bone-grafting materials. By penetrating international markets across Southeast Asia, Europe, and North America, U-NEURON adheres to its core “Commercial Monetization × R&D Reinvestment” model—utilizing consumer health revenues to fund clinical therapeutic pipelines, achieve profitable growth, and establish itself as an indispensable leader in regenerative medicine and aesthetics.
Disclaimer: This document contains forward-looking statements regarding future operations, clinical progression, and business outlooks of U-NEURON. Actual results may differ materially due to external variables including market competition, regulatory shifts, foreign exchange rates, and broader economic conditions. U-NEURON assumes no obligation to update these statements to reflect future events or circumstances.